Atai Beckley's Shareholders Get Their Say on a $3.8 Billion Bet on Psychedelic Medicine
Published on 07/25/2026 at 01:51 | Redaktion boerse-global.de
Atai Beckley has officially put the question to its investors: accept Eli Lilly's takeover offer or walk away. The company filed its definitive proxy statement (Form DEF 14A) with the SEC on Thursday, kicking off a shareholder vote that will determine whether the psychedelics-focused biotech becomes part of one of the world's largest pharmaceutical companies.
The terms are now locked in writing. Eli Lilly will pay $6.75 per share in cash, with the transaction slated to close before the end of September 2026. On top of that, shareholders receive Contingent Value Rights worth up to $2.50 per share, tied to clinical and regulatory milestones for Atai Beckley's two lead drug candidates. BPL-003, an intranasal formulation of 5-MeO-DMT targeting treatment-resistant depression, is already in a late-stage Phase 3 trial and has secured Breakthrough Therapy designation from the FDA. VLS-01, a buccal film-based compound for the same indication, is expected to yield topline data from another study in the fourth quarter of 2026. A third candidate, EMP-01, targets social anxiety disorder. The total package values Atai Beckley at roughly $3.8 billion, or $9.25 per share.
The stock currently trades at €6.30, virtually unchanged from the previous close. That flat session masks a dramatic run: shares have surged 71.20% over the past 30 trading days, a rally ignited when news of Lilly's interest first broke in mid-July. The immediate spike was even more violent — the stock jumped 59% in after-hours trading on the day of the initial offer.
Yet the momentum has clearly stalled. The share price now hovers near the fixed cash component of $6.75, a textbook pattern in merger arbitrage once the market prices in a high probability of deal completion. The Relative Strength Index sits at 75.4, firmly in overbought territory, while the 30-day annualized volatility stands at 120.87%. Both metrics reflect the jittery trading around the takeover narrative rather than any fresh fundamental catalyst.
Should investors sell immediately? Or is it worth buying Atai Beckley?
The stock remains roughly 20% below its all-time high of €7.85, reached on July 16 — the session immediately following the first deal announcement.
A First for Big Pharma in Psychedelics
Market observers view the transaction as a watershed moment for the nascent field of psychedelic-based therapies. No major pharmaceutical company has made this kind of entry before. Proponents argue that Lilly's commercial infrastructure could dramatically accelerate the path to market for BPL-003, though hard Phase 3 data for that compound is not expected until early 2029. The acquisition is, in effect, a multi-year bet on a pipeline that has yet to generate meaningful revenue — Atai Beckley posted just $3.5 million in sales and remains unprofitable, with Simply Wall St projecting losses for at least the next three years.
The regulatory environment has received a tailwind from an unexpected quarter. In April 2026, President Trump issued an executive order aimed at speeding up the development of psychedelic compounds. Competitor Compass Pathways has already benefited from an accelerated FDA review process for its COMP360 program.
Analysts Temper Expectations for a Wave of Deals
Jefferies analyst Tsai does not anticipate a broad takeover spree across the psychedelics sector, citing a shortage of both willing neuro-pharma buyers and suitable acquisition targets. He flags Compass Pathways and Definium Therapeutics — whose LSD-based candidate is also in Phase 3 — as possible next candidates, though unresolved logistics around administering such substances could slow any follow-on deals. For context, Otsuka paid $1.2 billion for Transcend Therapeutics in June, and AbbVie acquired Gilgamesh for the same amount in 2025. Tsai still considers the entire group of psychedelics developers undervalued.
Atai Beckley's own valuation metrics give reason for caution. The price-to-book ratio stands at 13.4, more than five times the industry average of 2.5. The takeover price is essentially a valuation of the clinical pipeline, not the operating business.
Atai Beckley at a turning point? This analysis reveals what investors need to know now.
Institutional Moves and the Path Forward
Cathie Wood's ARK Genomic Revolution ETF trimmed its position this week, selling roughly 1.12 million shares — a move consistent with the convergence of the stock price and the cash offer, which reduces the incentive for long-term holders to maintain exposure.
For current shareholders, the calculus is straightforward. The vote will determine whether the deal proceeds as planned. If approved, the transaction could close before the end of September. Whether Lilly's entry triggers a broader wave of M&A in the biotech space or remains an isolated strategic bet will depend on what other deals materialize in the months ahead.
Ad
Atai Beckley Stock: New Analysis - 25 July
Fresh Atai Beckley information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
